Oculis Holding AG (FRA:CR5) Days Payable: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CR5 Oculis Holding AG FRA:CR5
22 GF Score
Price €10.45
! 1 Warning Sign
View Full Analysis

What is Oculis Holding AG Days Payable?

Oculis Holding AG FRA:CR5 -2.79% 22 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates FRA:CR5 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 702 Biotechnology companies, Oculis Holding AG ranks worse than 142450% on this metric.

Oculis Holding AG's average Accounts Payable for the three months ended in Mar. 2026 was €3.43 Mil. Oculis Holding AG's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.00 Mil.

The historical rank and industry rank for Oculis Holding AG's Days Payable or its related term are showing as below:

FRA:CR5's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.1
* Ranked among companies with meaningful Days Payable only.

Oculis Holding AG's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Oculis Holding AG Days Payable Historical Data

* Premium members only.

The historical data trend for Oculis Holding AG's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG Days Payable Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oculis Holding AG Quarterly Data
Dec20 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:CR5 vs NVCT, AURA, CADL: Days Payable Comparison

For the Biotechnology subindustry, Oculis Holding AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Days Payable distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Days Payable falls into.


FRA:CR5
22GF Score
Oculis Holding AG FRA:CR5
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oculis Holding AG Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Oculis Holding AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (6.288 + 1.929) / 2 ) / 0*365
=4.1085 / 0*365
=N/A

Oculis Holding AG's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (1.929 + 4.94) / 2 ) / 0*365 / 4
=3.4345 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Oculis Holding AG (FRA:CR5) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Oculis Holding AG and its competitors. According to the industry distribution chart, Oculis Holding AG ranks #999999 out of 702 companies in the Biotechnology industry.
Is Oculis Holding AG's Days Payable too high?
Oculis Holding AG's current Days Payable is 0.00. Based on the distribution chart, Oculis Holding AG ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oculis Holding AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Days Payable compare to NVCT and AURA?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #999999 out of 702 companies for Days Payable. This places Oculis Holding AG in the lower half of its industry. The industry median Days Payable is 113.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Oculis Holding AG and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oculis Holding AG's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (FRA:CR5) has a current Days Payable of 0.00. The current Days Payable is 0.00. Oculis Holding AG's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Oculis Holding AG (FRA:CR5), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oculis Holding AG Business Description

Address Bahnhofstrasse 20, Zug, CHE, CH-6300
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
22GF Score

Get the complete analysis for FRA:CR5

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.45
Price